International Atomic Energy Agency-Sponsored Multination Study of Intra-Arterial Rhenium-188-Labeled Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results With Special Emphasis on Prognostic Value of Dosimetric Study

Seminars in Nuclear Medicine

Volumn 38, Issue 2, 2008, Pages

  Bernal, Patricia ^a   Raoul, Jean Luc ^b   Stare, Janez ^c   Sereegotov, Erdenechimeg ^d   Sundram, Felix X ^e   Kumar, Ajay ^f   Jeong, Jae Min ^g   Pusuwan, Pawana ^h   Divgi, Chaitanya ⁱ   Zanzonico, Pat ⁱ   Vidmar, Gaj ^c   Buscombe, John ^j   Chau, Trinh Thi Minh ^k   Saw, Maung Maung ^e   Chen, Shaoliang ^l   Ogbac, Ruben ^m   Dondi, Maurizio ⁿ   Padhy, Ajit Kumar ^e  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^b Centre Régional de Lutte Contre Le Cancer   (France)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

^d MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^g Seoul National University Hospital   (South Korea)

^h MAHIDOL UNIVERSITY   (Thailand)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j ROYAL FREE HOSPITAL   (United Kingdom)

^k CHO RAY HOSPITAL   (Viet Nam)

^l FUDAN UNIVERSITY   (China)

^m St Luke's Medical Centre   (Philippines)

ⁿ INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LIPIODOL RE 188; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; HYPOTENSION; LIVER CELL CARCINOMA; LIVER PAIN; LIVER TOXICITY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROGNOSIS; RADIATION ABSORPTION; RADIATION DOSE; STOMACH ULCER; TREATMENT RESPONSE; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; INTERNATIONAL AGENCIES; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR ENERGY; PROGNOSIS; RADIOISOTOPES; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RHENIUM;

EID: 38549173323     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2007.10.006     Document Type: Article

References (16)

1. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
2. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359 (2002) 1734-1739
3. 131I labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26 (1997) 1156-1161
4. 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: Preclinical study in a rabbit liver cancer model. J Nucl Med 44 (2003) 2033-2038
5. Lambert B., Bacher K., De Keukeleire K., et al. Re-188 HDD/Lipiodol for treatment of hepatocellular carcinoma: A feasibility study in patients with advanced cirrhosis. J Nucl Med 46 (2005) 1326-1332
6. Sundram F., Chau T.C., Onkhuudai P., et al. Preliminary results of transarterial Rhenium-188 Lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 31 (2004) 250-257
7. Bernal P., Raoul J.L., Vidmar G., et al. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: Results of an IAEA-sponsored multination study. Int J Radiat Oncol Biol Phys (2007) Aug 8 (Epub ahead of print)
8. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 28 (1998) 751-755
9. Knapp Jr. F.F., Turner J.H., Jeong J.-M., et al. Issues Associated with the use of Tungsten-188/Rhenium-188 Generator and Concentrator System and preparation of Re-188 HDD: A report. World J Nucl Med 3 (2004) 137-143
10. Leung D.A., Goin J.E., Sickles C., et al. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 12 (2001) 321-326
11. Salem R., and Hunter R.D. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66 suppl 2 (2006) S83-S84
12. Raoul J.L., Bretagne J.F., Caucanas P., et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of Iodine 131-labeled-lipiodol. Cancer 69 (1992) 346-352
13. Ryder S.D., Rizzi P.M., Metivier E., et al. Chemoembolisation with lipiodol and doxorubicin: Applicability in British patients with hepatocellular carcinoma. Gut 38 (1996) 125-128
14. 131I labelled lipiodol. Br J Surg 90 (2003) 1379-1383
15. 131I Lipiodol in patients with hepatocellular carcinoma. J Nucl Med 45 (2004) 612-618
16. Thierens H.M., Monsieurs M.A., and Bacher K. Patient dosimetry in radionuclide therapy: The whys and the wherefores. Nucl Med Commun 26 (2005) 593-599